Melanóma: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• PD-1 54
• BRAF 18
• PD-L1 21
• MEK 7
• TP53 0
• CTLA-4 10
• MAPK 2
• NRAS 8
• STING 0
• STAT3 0
• PRAME 3
• AKT 0
• PI3K 0
• BAP1 2
• VEGF 4
• mTOR 0
• ERK 0
• LAG-3 2
• RAS 2
• CTNNB1 0
• CD40 0
• CDKN2A 3
• TNF 0
• YAP 0
• PTEN 1
• JAK 0
• KIT 3
• KRAS 1
• JNK 0
• PPAR 0
• TIGIT 0
• ALK 0
• B7-H3 3
• BCL-2 0
• EZH2 0
• HIF-1 0
• IL-15 1
• NF1 2
• NLRP3 0
• NRF2 0
• AMPK 0
• HSP90 0
• CD47 0
• MYC 0
• PKM2 0
• AXL 1
• COX-2 0
• EGFR 0
• GPX4 0
• MET 1
• HDAC 1
• IDH 1
• IL-17 1
• MMP-9 0
• CDK4/6 0
• CXCR4 0
• FGFR 0
• HER2 3
• IGF1R 0
• PSMA 3

12+ intézményből 12, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Validation of artificial intelligence-based minibinders and inhibitors of Midkine in immune resistant tumours (MDK_MINIBINDERS)

  Fundacion Sector Publico Estatal Centro Nacional Investigaciones Oncologicas Carlos Iii· Madrid, Spanyolország· EU contribution 150 000 EUR· until 2028. ápr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Light-triggered Ultra-precise Carbon-enhanced phycocyanin Engineered Needles for Therapy (LUCENT)

  Univerzita Palackeho V Olomouci· Olomouc, Csehország· EU contribution 191 918 EUR· until 2028. aug.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeted therapy to block melanoma progression through peptide phage-display profiling of melanoma cells and derived extracellular vesicles (Target-MelaneX)

  I3s - Instituto de Investigacao e Inovacao Em Saude Da Universidade Do Porto· Porto, Portugália· EU contribution 207 183 EUR· until 2028. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC

  THz-FIR Colour Imaging of Skin Condition Based on Analysis of Its Thermal Emission (THz-Skin)

  Ita-Suomen Yliopisto· Kuopio, Finnország· EU contribution 2 998 913 EUR· until 2030. jan.· 5 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Capturing UV Sunlight Using Hydrogen-Bond Networks: Organic Sun Screens for Skin Protection (CUSHOSP)

  United Nations Educational Scientific and Cultural Organization· Paris, Franciaország· EU contribution 150 000 EUR· until 2027. jún.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  HYPERspectral monitoring for accurate light-based SKIN cancer treatment (HyperSKIN)

  Politecnico di Milano· Milano, Olaszország· EU contribution 150 000 EUR· until 2027. febr.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Microneedle array-Mediated Combinatorial Photodynamic Raman Nanotheranostics for simultaneous Cancer Diagnosis and Therapy (MNA-Cancer)

  The Queen's University of Belfast· Belfast, Egyesült Királyság· EU contribution 276 188 EUR· until 2027. jún.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Theranostic magnetic nano-based codelivery system for boosting cancer immunotherapy (MultiTheranostic)

  International Iberian Nanotechnology Laboratory· Braga, Portugália· EU contribution 172 619 EUR· until 2026. dec.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Hi-NEAT (Hierarchical Nanoengineered Assemblies of Titania) sensor

  Malmo Universitet· Malmoe, Svédország· EU contribution 222 728 EUR· until 2027. máj.

• European Commission (Horizon Europe) · HORIZON-ERC

  Melanosomes as cancer immune modulators: a novel paradigm in melanoma immunity (melanosomeEVimmune)

  Tel Aviv University· Tel Aviv, Izrael· EU contribution 2 515 625 EUR· until 2028. dec.

  The disease is named only in the funder's project summary, not in the title.

10 of 12 running projects, newest first. Listed amounts together: 11,7 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  NCT07492680· Bristol-Myers Squibb· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 51
• Organoids 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 22
• Gene Expression Profiling 116
• Sequence Analysis, RNA 9
• Whole Genome Sequencing 6
• Exome Sequencing 7
• Proteomics 47
• Metabolomics 20
• Mass Spectrometry 10
• Flow Cytometry 65
• Immunohistochemistry 106
• Liquid Biopsy 12
• Circulating Tumor DNA 37
• Xenograft Model Antitumor Assays 121
• Positron-Emission Tomography 31
• Magnetic Resonance Imaging 57
• Machine Learning 49
• Deep Learning 44
• Cohort Studies 78
• Genome-Wide Association Study 22

• Benchmarking cell segmentation in two Spatialomics platforms with open-source software.

  Sci Rep, 2026. okt.

• Spatial Proteomics as a Potential Decision-Support Layer for Early Melanoma: A Narrative Review.

  Int J Dermatol, 2026. okt.

• Mapping of the hSOX10 Proximal Protein Interactome in Human Melanoma.

  J Proteome Res, 2026. máj.

• Bioassay-guided separation and identification of the anticancer composition from Curcuma longa L. by the combination strategy of methanol gradient countercurrent chromatography and ultra-high-performance liquid chromatography coupled with high-resolution mass spectrometry.

  J Sep Sci, 2022. nov.

• Hydroxylation of CYP11A1-derived products of vitamin D3 metabolism by human and mouse CYP27B1.

  Drug Metab Dispos, 2013. márc.

• Combined proteomic and molecular approaches for cloning and characterization of copper-zinc superoxide dismutase (Cu, Zn-SOD2) from garlic (Allium sativum).

  Mol Biotechnol, 2012. szept.

• Antiproliferative activity of methylated analogues of E- and Z-resveratrol.

  Z Naturforsch C J Biosci, 2007. jan.

• Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity.

  J Inorg Biochem, 2006. jan.

• Identification of o-quinone/quinone methide metabolites of quercetin in a cellular in vitro system.

  FEBS Lett, 2002. jún.

• Investigation on the iodination reaction of methylene blue by liquid chromatography-mass spectrometry with ionspray ionisation.

  J Chromatogr A, 1999. aug.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.